Dietary intervention for children with Juvenile Idiopathic Arthritis
Official title: Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis: Interventional, Exploratory Single-center, Randomized, Controlled, Open-label, add-on Study
Run by Meyer Children's Hospital IRCCS · NCT06874608 · Data updated 2026-11-12
This study is testing if a special diet without certain ingredients can help children with Juvenile Idiopathic Arthritis feel better over four weeks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 6 Years to 18 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Florence) |
| Status | Recruiting |
| Started | December 12, 2024 |
| Main results expected | May 15, 2025 |
| Study ends | November 15, 2025 |
| Registry record updated | March 13, 2025 |
| Trial ID | NCT06874608 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 6 to 18 with a confirmed diagnosis of mild to moderate JIA who have not responded adequately to current pharmacological therapies.
✕Probably not a fit
Patients requiring systemic immunosuppressive therapy for active uveitis or those on systemic corticosteroids may not benefit from this dietary intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot project evaluates the effectiveness of a complete, polymeric, fiber, lactose, and gluten-free diet in children aged 6 to 18 with Juvenile Idiopathic Arthritis (JIA). The study aims to determine if a 4-week exclusion diet can lead to improvements in disease activity, similar to findings in other inflammatory conditions. Participants will be assessed for their response to the diet using the Juvenile Arthritis Disease Activity Score (JADAS10).
Why it matters
Potential benefit: If successful, this dietary approach could provide a non-pharmacological treatment option for managing symptoms of JIA in children.
How similar studies have gone: Previous studies in other inflammatory diseases have shown promising results with similar dietary interventions, suggesting potential for success in this context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of juvenile idiopathic arthritis (JIA) in the forms of enthesitis-related arthritis and oligoarticular forms according to the ILAR 2001 criteria (https://medicalcriteria.com/web/reujia/); * Age between 6 and 18 years (not yet 18); * Active disease of mild to moderate severity, assessed through the Juvenile - Arthritis Disease Activity Score (JADAS10) tool (Trincianti C. et al., American College Rheumatology, 2021); * For study groups 2 and 3: failure of ongoing pharmacological therapy at the time of screening, defined as a failure to achieve at least a 20% reduction in JADAS10 values after 3 months of initiating DMARD therapy or biologic medication, or if the disease is inactive on such therapy, a 20% increase in those values; * Signed informed consent. Exclusion Criteria: * Patients requiring systemic immunosuppressive therapy for active uveitis; * Patients undergoing therapy with systemic corticosteroids (defined as prednisone equivalent \>0.5 mg/kg for \>7 days) or intra-articular corticosteroids in the 3 months prior to enrollment; * Patients with fecal calprotectin values \> 250 mcg/g at the time of screening; * Use of antibiotics in the month prior to enrollment.
Where it's running
-
AOU Meyer IRCCS
Florence, Italy Recruiting
Study contacts
- Study coordinator: Polo Lionetti, MD, PhD, Ordinary Professor
- Email: paolo.lionetti@unifi.it
- Phone: +39 3398416059
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting the course of early-onset juvenile idiopathic arthritis using a multidimensional model
Researchers are testing a comprehensive model to predict how early-onset JIA will progress in affected children and how a small control group with iridocyclitis compares.
-
Understanding subtypes of chronic musculoskeletal pain in youth
This observational study tests whether distinct brain and immune profiles can explain chronic musculoskeletal pain in teens and young adults to guide more precise treatments.
-
Open-label extension with filgotinib for juvenile idiopathic arthritis
This long-term open-label extension sees if filgotinib stays safe and continues to control symptoms in children aged 8–17 with polyarticular or systemic juvenile idiopathic arthritis who benefited from earlier treatment.
-
Structured or video-game–based core stabilization for children with juvenile idiopathic arthritis
This study will try whether a regular structured core exercise program or a fun exergaming-based core program helps children aged 8–13 with juvenile idiopathic arthritis improve strength, reduce pain, and move better.
-
Tofacitinib in Juvenile Idiopathic Arthritis
This study looks at real-world use of tofacitinib to see if it helps control Juvenile Idiopathic Arthritis in kids over about 12 months.
-
Parents' pain catastrophizing in children with juvenile idiopathic arthritis
See if parents' worrying and negative thoughts about their child's pain are linked to treatment adherence and biopsychosocial outcomes in children with juvenile idiopathic arthritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.